NCT00726544终止2 期
A Randomized, Double-blind, Placebo Controlled, Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 100
- 试验地点
- 17
- 主要终点
- The incidence of the clinical composite of death (all-cause mortality), stroke, coma, seizures, renal failure, or acute myocardial infarction (AMI)
研究概览
简要总结
The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female;
- •≥18 to ≤75 years of age;
- •Diagnosis of TMA based on presence of:
- •Thrombocytopenia, defined as a platelet count <100 x 109 per liter;
- •Microangiopathic hemolytic anemia, defined by negative findings on direct antiglobulin test, and evidence of accelerated red blood cell (RBC) production and destruction); AND
- •Absence of a clinically apparent alternative explanation for thrombocytopenia and anemia, e.g., disseminated intravascular coagulation (DIC), eclampsia, HELLP syndrome, Evans syndrome;
- •Females: non-pregnant and commit to use of effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment;
- •Males: commit to use of a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment;
- •Not received an unlicensed investigational agent (drug, device, or blood-derived product) within 30 days prior to randomization, and may not receive such an investigational agent in the 30 days post-randomization (note: investigational use for treatment of TMA of a licensed immunomodulator, e.g., rituximab, is permitted at any time relative to randomization);
- •Capable of understanding and complying with the protocol, and he/she (or a legal representative) must have signed the informed consent document prior to performance of any study-related procedures.
- •Patients who have again become acutely ill following recent treatment and achievement of a brief remission of acute TMA may be enrolled in the study if ALL of the following conditions are met:
- •Disease activity in the patient in unabated (e.g. persistent thrombocytopenia and microangiopathic hemolytic anemia with ongoing neurological symptoms and/or troponin elevation);
- •The last plasma exchange of the patient's preceding course of treatment occurred at least 7 days prior;
- •The patient did not undergo splenectomy during the preceding course of treatment;
- •The new course of plasma exchange has not been ongoing for more than 3 days.
排除标准
- •Females: pregnant or <24 hours post-partum, or breastfeeding;
- •History of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days;
- •Disseminated malignancy or other co-morbid illness limiting life expectancy to ≤3 months independent of the TMA disorder.
- •Diagnosis other than TMA which can account for the findings of thrombocytopenia and hemolytic anemia (e.g., DIC, HELLP syndrome, Evans syndrome);
- •Diagnosis of DIC verified by laboratory values for D-dimer, fibrinogen, prothrombin time (PT), and activated partial thromboplastin time (aPTT).
- •Patients who have again become acutely ill following recent treatment and achievement of a brief remission of acute TMA may not be enrolled in the study if ANY of the following conditions are met:
- •The last plasma exchange of the patient's preceding course of treatment occurred less than 7 days prior;
- •The patient underwent splenectomy during the preceding course of treatment;
- •The new course of plasma exchange has been ongoing for more than 3 days.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: ARC 1779 Placebo (Drug)
Low Dose
Active Comparator
干预措施: ARC1779 Injection (Drug)
Medium Dose
Active Comparator
干预措施: ARC1779 Injection (Drug)
High Dose
Active Comparator
干预措施: ARC1779 Injection (Drug)
结局指标
主要结局
The incidence of the clinical composite of death (all-cause mortality), stroke, coma, seizures, renal failure, or acute myocardial infarction (AMI)
时间窗: 6 weeks post randomization
次要结局
- Neurocognitive function is to be assessed with the CogState® test system.(Once during the hospitalization period and again at the 6 week clinic visit.)
- The incidence of death, stroke, or acute renal failure/injury requiring dialysis is to be assessed.(During the extended clinical follow-up for each patient from the time of the 6 week clinic visit until the study is closed.)
- Safety- and efficacy-related clinical laboratory parameters and biomarkers will be analyzed in relation to ARC1779 exposure in terms of the dose administered and the observed plasma concentration.(During initial hospitalization and at 6 week clinic visit.)
- The incidence of the composite of complications associated with plasma exchange therapy (i.e., catheter-related infection, thrombosis, internal hemorrhage, or pneumothorax) is to be assessed.(During initial hospitalization and at the 6 week clinic visit.)
研究者
研究点 (17)
Loading locations...
相似试验
终止
1 期
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)Alpha-1 Antitrypsin DeficiencyNCT02363946Arrowhead Pharmaceuticals65
已完成
2 期
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of SchizophreniaSchizophreniaNCT00265551Wyeth is now a wholly owned subsidiary of Pfizer300
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsHealthy VolunteersNCT06193031Insmed Incorporated24
Unknown
1 期
A Single Ascending Dose Study Of CY150112 After Single Oral Administration in Healthy Chinese SubjectsSchizophreniaNCT04839926Jiangsu Nhwa Pharmaceutical Co., Ltd.60
进行中（未招募）
1 期
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee OsteoarthritisOsteo Arthritis KneeKnee OsteoarthritisOsteoarthritis, KneeNCT05835895Genascence Corporation67